Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
38.460,08 +907,92 (+2,42%) EUR/USD
1,0701 0,0000 (-0,00%) Bitcoin EUR
59.951,98 -2.155,94 (-3,47%) CMC Crypto 200
1.385,27 -38,83 (-2,72%)
Altimmune, Inc. (0A4C.L)
| Chiusura precedente | 7,69 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 54.660 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,06 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,39 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAltimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes
GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Louis J. Aronne, Founder and Director of the Center for Weight Management at Weill-Cornell Medical Center, and a leading authority in obesity, will present the results of its 24-week clinical trial of pemvidutide in the treatment of subjects with overweight or obesity in an oral presentation at the 59th Annual Meeting of the European Associatio
- GlobeNewswire
Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight
Top-line 48-week results from the trial expected Q4 2023GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesi
- GlobeNewswire
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Wells Fargo 2023 Healthcare Conference in Everett, MAWednesday, September 6, 2023Fireside chat at 3:45 pm Eastern Time Morgan Stanley 21st Annual Global Healthcare Conference in New York, NYWednesday, September 13, 2023F
